Potential for trials in Russia "enormous", says ClinStar

By Gareth Macdonald

- Last updated on GMT

Related tags: Russia, Clinical trial

Russia, the Ukraine and Belarus have emerged as destinations for clinical studies and now offer “enormous” potential according to US-based CRO ClinStar.

Roger Price, director of European business development director at the contract research organisation (CRO) told Outsourcing-pharma that because fewer trials are conducted in the region there is less competition for patients than in the US.

Price also said that the legacy of the USSR's centralised system means that across the region health care provision is focused at key hubs which, he suggested, offers significant benefits in terms of both recruitment and monitoring.

He explained that: “When we do a study we can go to these hospitals, they have databases and we can access those [patients​]” and added that developing effective relationships with such institutions is critical to success in the region.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars